These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 6698743)
1. Imipramine inhibiton of ragweed allergic conjunctivitis. Sugar J; Nyberg M; Bernstein J; Barlow A; Slater W Invest Ophthalmol Vis Sci; 1984 Feb; 25(2):217-8. PubMed ID: 6698743 [TBL] [Abstract][Full Text] [Related]
2. Treatment of ragweed allergic conjunctivitis with 2% cromolyn solution in unit doses. Nizami RM Ann Allergy; 1981 Jul; 47(1):5-7. PubMed ID: 6789720 [TBL] [Abstract][Full Text] [Related]
3. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis. Blumenthal MN; Schwartz RH; Kaiser H Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577 [TBL] [Abstract][Full Text] [Related]
4. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis-a controlled, double-blind clinical trial. Miller J; Wolf EH Ann Allergy; 1975 Aug; 35(2):81-6. PubMed ID: 1096685 [TBL] [Abstract][Full Text] [Related]
5. [Allergy to ragweed in the Rhone-Alpes and consumption of anti-allergics]. Christophe B; Gillet A; Mejecase M Eur Ann Allergy Clin Immunol; 2004 Nov; 36(9):333-6. PubMed ID: 15633370 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Melamed J; Schwartz RH; Hirsch SR; Cohen SH Ann Allergy; 1994 Jul; 73(1):57-66. PubMed ID: 8030804 [TBL] [Abstract][Full Text] [Related]
7. First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. Juniper EF; Guyatt GH; Ferrie PJ; Griffith LE CMAJ; 1997 Apr; 156(8):1123-31. PubMed ID: 9141982 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Abelson MB; Greiner JV Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212 [TBL] [Abstract][Full Text] [Related]
9. [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children]. Endre L Orv Hetil; 2003 Apr; 144(14):665-7. PubMed ID: 12795028 [TBL] [Abstract][Full Text] [Related]
10. A double-blind clinical trial wtih cromoglycate eye drops in patients with atopic conjunctivitis. Simon-Licht IF; Dieges PH Ann Allergy; 1982 Oct; 49(4):220-4. PubMed ID: 6812469 [TBL] [Abstract][Full Text] [Related]
11. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial. Cavanagh B; Gomes PJ; Starr CE; Nichols KK; Brady TC Ophthalmol Ther; 2022 Aug; 11(4):1449-1461. PubMed ID: 35585427 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Miyake-Kashima M; Takano Y; Tanaka M; Satake Y; Kawakita T; Dogru M; Asano-Kato N; Fukagawa K; Fujishima H Jpn J Ophthalmol; 2004; 48(6):587-90. PubMed ID: 15592786 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Hordijk GJ; Antvelink JB; Luwema RA Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374 [TBL] [Abstract][Full Text] [Related]
18. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Leonardi A; Zafirakis P Curr Med Res Opin; 2004 Aug; 20(8):1167-73. PubMed ID: 15324519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]